Please login to the form below

Not currently logged in
Email:
Password:

financial results

This page shows the latest financial results news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity

Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity

Novo Nordisk is claiming a 14% share of the new-to-brand prescription market with Ozempic, and says “initial feedback from prescribers and payers is positive” in its first-half results ... Obesity drug dropped. In an R&D update accompanying the

Latest news

  • The secret of success The secret of success

    How does this relate to the business models of life science companies and the current crop of financial results? ... Well, just as in the competition between species, we can see a distinct polarisation of results.

  • Shire claims EU approval for haemophilia A drug Adynovi Shire claims EU approval for haemophilia A drug Adynovi

    figures for individual haemophilia products in its financial results is estimated to have made around $300m last year - or around 10% of its total franchise.

  • Biosimilars eat into J&J's Remicade sales Biosimilars eat into J&J's Remicade sales

    This is the first set of financial results for J&J since it closed the acquisition of Swiss biotech Actelion, a specialist in pulmonary arterial hypertension (PAH), on June 16.

  • Roche in Roche in "unprecedented" launch period for new medicines

    The launch of AbbVie-partnered Venclexta came too late in the quarter to feature in the financial results.

  • Biogen's CEO Scangos to step down Biogen's CEO Scangos to step down

    The highlight of Biogen's first-half results statement was not the financial performance of the company but the news that chief executive George Scangos is to step down. ... Scangos' departure comes as Biogen reported an improved set of financial results,

More from news
Approximately 70 fully matching, plus 109 partially matching documents found.

Latest Intelligence

  • Deal Watch - May 2017 Deal Watch - May 2017

    some financial companies to re-emerge as Barbarians.  The 2008 financial crash is a salutary reminder. ... What happens next?    Assuming the deal is completed, DW predicts the new Stada will start to hunt for product and company acquisitions to

  • Deal Watch August 2016 Deal Watch August 2016

    company rather than seeking a short term financial 'fix' to improve its financial results.”. ... In the same way that the asset acquisition deal between AstraZeneca and Pfizer had the financial structure of a licence, so too does the Pfizer acquisition

  • Technology: the missing link in true patient engagement? Technology: the missing link in true patient engagement?

    This comes at a huge financial cost, and results in suboptimal patient outcomes. ... While manual adherence programmes with assigned nurses have yielded positive outcomes, it isn't always possible to provide this widely due to financial and resource

  • Deal Watch April 2016 Deal Watch April 2016

    term financial 'fix' to improve its financial results. ... The deal with Nimbus did not excite investors and they were even less impressed when Gilead reported first quarter results showing sales growth of 4% and full year guidance of $30bn

  • Who tops the pharma list? Who tops the pharma list?

    Chris Ross, with the help of healthcare analysts GlobalData, takes a New Year look at the past, present and future of global pharma, and asks: what’s trending? 

More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest appointments

  • BMS appoints Peter Arduini to board of directors BMS appoints Peter Arduini to board of directors

    Lamberto Andreotti, chairman of BMS, said: “Pete is a confident and engaging leader who has delivered tremendous results throughout his career. ... His commercial, financial and operational experience, along with a deep understanding of healthcare,

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics